Henry Jardel

Vannes, FR 
Vannes, FR 

Overview

Henry Jardel practices practicing medicine in Vannes, France.

His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, Multiple Myeloma, and Chronic Myelogenous Leukemia (CML).

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Vannes, France
Other Locations
Lyon, France
CHD de la Roche Sur Yon
La Roche, France
Perigueux, France
Nantes, 44093, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Methotrexate, Cyclophosphamide
Study Phase: Phase 2
Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
Enrollment Status: Completed
Publish Date: April 10, 2018
View 1 Less Clinical Trial

10 Total Publications

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Journal: Haematologica
Published: February 08, 2022

Frequently Asked Questions about Henry Jardel

Is Henry Jardel a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Henry Jardel is classified as an Experienced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Henry Jardel participate in research or clinical trials?

Yes. Henry Jardel has published 10 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Henry Jardel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jardel's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile